Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.53% in Regular Trading, Stock Offering Dilution Overshadows Sanofi Milestone Progress

Market Focus10-16

On October 16, Recursion Pharmaceuticals, Inc. fell 8.53% in Regular Trading, trading at $3.805 per share, with turnover of $17.2443 million.

The main catalyst was the market's negative reaction to the company's newly priced equity offering, even as its Sanofi collaboration delivered a milestone update.

Recursion Pharmaceuticals, Inc. said it priced 61.5 million shares at $3.25 each for gross proceeds of about $200 million, with the transaction expected to close on Friday. Separately, Sanofi selected the first drug candidate from the partners' research collaboration, triggering a $10 million milestone payment. The oral small-molecule inflammatory disease candidate has entered Sanofi's pipeline and is currently planned to begin phase 1 clinical study in 2027. Recursion Pharmaceuticals, Inc. said total upfront and milestone payments under the collaboration have reached $144 million, with eligibility for more than $300 million in additional milestones plus double-digit royalties on net sales if approved. Despite that operational progress, the current share move suggests dilution pressure from the financing is weighing more heavily on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121887044?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-16 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121887044","market":"us","top_or_hot":-1,"title":"Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.53% in Regular Trading, Stock Offering Dilution Overshadows Sanofi Milestone Progress","media":"Market Focus","content":"<p><p>On October 16, Recursion Pharmaceuticals, Inc. fell 8.53% in Regular Trading, trading at $3.805 per share, with turnover of $17.2443 million.</p><p>The main catalyst was the market's negative reaction to the company's newly priced equity offering, even as its Sanofi collaboration delivered a milestone update.</p><p>Recursion Pharmaceuticals, Inc. said it priced 61.5 million shares at $3.25 each for gross proceeds of about $200 million, with the transaction expected to close on Friday. Separately, Sanofi selected the first drug candidate from the partners' research collaboration, triggering a $10 million milestone payment. The oral small-molecule inflammatory disease candidate has entered Sanofi's pipeline and is currently planned to begin phase 1 clinical study in 2027. Recursion Pharmaceuticals, Inc. said total upfront and milestone payments under the collaboration have reached $144 million, with eligibility for more than $300 million in additional milestones plus double-digit royalties on net sales if approved. Despite that operational progress, the current share move suggests dilution pressure from the financing is weighing more heavily on sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.53% in Regular Trading, Stock Offering Dilution Overshadows Sanofi Milestone Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.53% in Regular Trading, Stock Offering Dilution Overshadows Sanofi Milestone Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-16 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 16, Recursion Pharmaceuticals, Inc. fell 8.53% in Regular Trading, trading at $3.805 per share, with turnover of $17.2443 million.</p><p>The main catalyst was the market's negative reaction to the company's newly priced equity offering, even as its Sanofi collaboration delivered a milestone update.</p><p>Recursion Pharmaceuticals, Inc. said it priced 61.5 million shares at $3.25 each for gross proceeds of about $200 million, with the transaction expected to close on Friday. Separately, Sanofi selected the first drug candidate from the partners' research collaboration, triggering a $10 million milestone payment. The oral small-molecule inflammatory disease candidate has entered Sanofi's pipeline and is currently planned to begin phase 1 clinical study in 2027. Recursion Pharmaceuticals, Inc. said total upfront and milestone payments under the collaboration have reached $144 million, with eligibility for more than $300 million in additional milestones plus double-digit royalties on net sales if approved. Despite that operational progress, the current share move suggests dilution pressure from the financing is weighing more heavily on sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1121887044","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121887044","pubTimestamp":1792158686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 16, Recursion Pharmaceuticals, Inc. fell 8.53% in Regular Trading, trading at $3.805 per share, with turnover of $17.2443 million.The main catalyst was the market's negative reaction to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"变动警报|Recursion Pharmaceuticals, Inc. 常规交易中下跌 8.53%，股票发行稀释掩盖了赛诺菲的里程碑进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"On October 16, Recursion Pharmaceuticals, Inc. fell 8.53% in Regular Trading, trading at $3.805 per share, with turnover of $17.2443 million.The main catalyst was the market's negative reaction to the company's newly priced equity offering, even as its Sanofi collaboration delivered a milestone update.Recursion Pharmaceuticals, Inc. said it priced 61.5 million shares at $3.25 each for gross proceeds of about $200 million, with the transaction expected to close on Friday. Separately, Sanofi selected the first drug candidate from the partners' research collaboration, triggering a $10 million milestone payment. The oral small-molecule inflammatory disease candidate has entered Sanofi's pipeline and is currently planned to begin phase 1 clinical study in 2027. Recursion Pharmaceuticals, Inc. said total upfront and milestone payments under the collaboration have reached $144 million, with eligibility for more than $300 million in additional milestones plus double-digit royalties on net sales if approved. Despite that operational progress, the current share move suggests dilution pressure from the financing is weighing more heavily on sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121887044","isCrawlerRequest":true}